Subscribe to Here’s the Deal, our politics
newsletter for analysis you won’t find anywhere else.
Thank you. Please check your inbox to confirm.
U.S. health advisers are reviewing Merck's closely watched COVID-19 pill, which could become the first easy-to-use drug for American patients.
An influential U.S. advisory panel will discuss expanding eligibility for COVID-19 vaccine booster shots to all adults Friday, a move that could make the shots available as early as this weekend.
If the Centers for Disease Control and Prevention agrees, tens of millions more Americans could have three doses of protection ahead of the new year. Anyone who got the one-dose Johnson & Johnson vaccine can already get a booster.
Pfizer is submitting its experimental pill for COVID-19 for U.S. authorization, setting the stage for a likely launch of the promising therapy in coming weeks.
Califf served as FDA commissioner for the last 11 months of President Barack Obama’s second term.
Since the beginning of the pandemic last year, researchers worldwide have been racing to find a pill to treat COVID-19 that can be taken at home to ease symptoms, speed recovery and keep people out of the hospital.
Britain has granted a conditional authorization to Merck's coronavirus antiviral. It's the first pill shown to successfully treat COVID-19.
Next week, advisers to the CDC will discuss which youngsters should get vaccinated. In the meantime, Pfizer plans to begin shipping millions of vials of the new doses to vaccination sites.
The vote Tuesday by the Food and Drug Administration panel moves the nation closer to vaccinating children ages 5 to 11. The FDA isn't bound by the recommendation and is expected to make its own decision within days.
The U.S. moved a step closer to expanding COVID-19 vaccinations for millions more children as a panel of government advisers on Tuesday endorsed kid-size doses of Pfizer's shots for 5- to 11-year-olds.
Support Provided By: